| Outcome Measures: |
Primary: Part 1: AEs, Assessment AEs by frequency and severity in the part 1, Baseline up to Days 15|Part 1: Maximum plasma concentration (Cmax) of SSS17, Plasma samples will be collected and Cmax will be assessed in the part 1, Up to 336 hours post-dose|Part 1: Area under the concentration-time curve (AUC) of plasma concentration of SSS17, Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 1, Up to 336 hours post-dose|Part 1: Time-to-Cmax (Tmax) of SSS 17, Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 1, Up to 336 hours post-dose|Part 1: Elimination terminal half-life (t1/2) of SSS17, Plasma samples will be collected and the t1/2 will be assessed in the part 1, Up to 336 hours post-dose|Part 1: . Total amount of SSS17 excreted in urine over 72 hours (Ae0-72), Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed in the part 1, Up to 72 hours post-dose|Part 1: Fraction of SSS17 excretion during each collection interval (Fe0-72), Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed in the part 1, Up to 72 hours post-dose|Part 1: Renal clearance (CLR) of SSS17, Urine sample will be collected at pre-specified intervals and CLR will be assessed in the part 1, Up to 72 hours post-dose|Part 2: AEs, Assessment AEs by frequency and severity in the part 2, Up to Days 33 or 57|Part 2: Steady state minimal concentration (Css_min) of SSS17, Plasma samples will be collected and Css_min will be assessed in the part 2, Up to Days 33 or 57|Part 2: Steady state maximum concentration (Css_max) of SSS17, Plasma samples will be collected and Css_max will be assessed in the part 2, Up to Days 33 or 57|Part 2: Steady state average concentration (Css_av) of SSS17, Plasma samples will be collected and Css_av will be assessed in the part 2, Up to Days 33 or 57|Part 2: Area under the concentration-time curve of plasma concentration of SSS17 within the interval of administration after reaching steady state (AUC0-τ), Plasma samples will be collected and the AUC from zero to τ will be assessed, Up to Days 33 or 57|Part 3: Maximum plasma concentration (Cmax) of SSS17, Plasma samples will be collected and Cmax will be assessed in the part 3, Up to Days 44|Part 3: Area under the concentration-time curve (AUC) of plasma concentration of SSS17, Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 3, Up to Days 44|Part 3: Time-to-Cmax (Tmax) of SSS 17, Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 3, Up to Days 44|Part 3: Elimination terminal half-life (t1/2) of SSS17, Plasma samples will be collected and the t1/2 will be assessed in the part 3, Up to Days 44 | Secondary: Part 1: EPO concentrations, Change of EPO concentrations from baseline following SSS17 in the part 1, Up to 168 hours post-dose|Part 1: VEGF concentrations, Change of VEGF concentrations from baseline following SSS17 in the part 1, Up to 168 hours post-dose|Part 1: Change of hepcidin from baseline, Change of serum hepcidin concentrations from baseline following SSS17 in the part 1, Up to 168 hours post-dose|Part 1: Change of RTC from baseline, Change of RTC from baseline following SSS17 in the part 1, Baseline up to Days 15|Part 1: Change of RBC from baseline, Change of RBC from baseline following SSS17 in the part 1, Baseline up to Days 15|Part 1: Change of Hgb from baseline, Change of Hgb from baseline following SSS17 in the part 1, Baseline up to Days 15|Part 2: EPO concentrations, Change of EPO concentrations from baseline following SSS17 in the part 2, Up to Days 33 or 57|Part 2: VEGF concentrations, Change of VEGF concentrations from baseline following SSS17 in the part 2, Up to Days 33 or 57|Part 2: Change of hepcidin from baseline, Change of serum hepcidin concentrations from baseline following SSS17 in the part 2, Up to Days 33 or 57|Part 2: Change of RTC from baseline, Change of RTC from baseline following SSS17 in the part 2, Baseline up to Days 33 or 57|Part 2: Change of RBC from baseline, Change of RBC from baseline following SSS17 in the part 2, Baseline up to Days 33 or 57|Part 2: Change of Hgb from baseline, Change of Hgb from baseline following SSS17 in the part 2, Baseline up to Days 33 or 57|Part 3: AEs, Assessment AEs by frequency and severity in the part 3, Up to Days 44|Part 3: EPO concentrations, Change of EPO concentrations from baseline following SSS17 in the part 3, Up to Days 44|Part 3: VEGF concentrations, Change of VEGF concentrations from baseline following SSS17 in the part 3, Up to Days 44|Part 3: Change of hepcidin from baseline, Change of serum hepcidin concentrations from baseline following SSS17 in the part 3, Up to Days 44|Part 3: Change of RTC from baseline, Change of RTC from baseline following SSS17 in the part 3, Baseline up to Days 44|Part 3: Change of RBC from baseline, Change of RBC from baseline following SSS17 in the part 3, Baseline up to Days 44|Part 3: Change of Hgb from baseline, Change of Hgb from baseline following SSS17 in the part 3, Baseline up to Days 44
|
